Interactions Between Serotypes of Dengue Highlight Epidemiological Impact of Cross-immunity

Overview

Journal J R Soc Interface

Specialties Biology
Biomedical Engineering
Biophysics

Date 2013 Jul 5

PMID 23825116

Citations 163

Authors

Nicholas G Reich

Sourya Shrestha

Aaron A King

Pejman Rohani

Justin Lessler

Siripen Kalayanarooj

In-Kyu Yoon

Robert V Gibbons

Donald S Burke

Derek A T Cummings

Affiliations

Soon will be listed here.

Abstract

Dengue, a mosquito-borne virus of humans, infects over 50 million people annually. Infection with any of the four dengue serotypes induces protective immunity to that serotype, but does not confer long-term protection against infection by other serotypes. The immunological interactions between serotypes are of central importance in understanding epidemiological dynamics and anticipating the impact of dengue vaccines. We analysed a 38-year time series with 12 197 serotyped dengue infections from a hospital in Bangkok, Thailand. Using novel mechanistic models to represent different hypothesized immune interactions between serotypes, we found strong evidence that infection with dengue provides substantial short-term cross-protection against other serotypes (approx. 1-3 years). This is the first quantitative evidence that short-term cross-protection exists since human experimental infection studies performed in the 1950s. These findings will impact strategies for designing dengue vaccine studies, future multi-strain modelling efforts, and our understanding of evolutionary pressures in multi-strain disease systems.

Citing Articles

Enhancing surveillance for dengue fever in Oyo State, Nigeria - a one health approach.

Animasaun O, Shaibu J, Akomolafe B, Animasaun O, Niyang P, Olugbade O One Health Outlook. 2025; 7(1):5.

PMID: 39875932 PMC: 11776199. DOI: 10.1186/s42522-024-00121-9.

Current status of the development of dengue vaccines.

Lee M, Long C, Poh C Vaccine X. 2025; 22():100604.

PMID: 39830640 PMC: 11741033. DOI: 10.1016/j.jvacx.2024.100604.

Predicting the infecting dengue serotype from antibody titre data using machine learning.

Cracknell Daniels B, Buddhari D, Hunsawong T, Iamsirithaworn S, Farmer A, Cummings D PLoS Comput Biol. 2024; 20(12):e1012188.

PMID: 39715263 PMC: 11706371. DOI: 10.1371/journal.pcbi.1012188.

Modelling the mechanisms of antibody mixtures in viral infections: the cases of sequential homologous and heterologous dengue infections.

Dugourd-Camus C, Ferreira C, Adimy M J R Soc Interface. 2024; 21(219):20240182.

PMID: 39406340 PMC: 11523103. DOI: 10.1098/rsif.2024.0182.

An effective pan-serotype dengue vaccine and enhanced control strategies could help in reducing the severe dengue burden in Bangladesh-A perspective.

Kayesh M, Nazneen H, Kohara M, Tsukiyama-Kohara K Front Microbiol. 2024; 15:1423044.

PMID: 39228383 PMC: 11368799. DOI: 10.3389/fmicb.2024.1423044.

References

Sabin A . The dengue group of viruses and its family relationships. Bacteriol Rev. 1950; 14(3):225-32. View

Guzman M, Alvarez M, Halstead S . Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013; 158(7):1445-59. DOI: 10.1007/s00705-013-1645-3. View

Muelenaer P, Henderson F, Hemming V, Walsh E, Anderson L, Prince G . Group-specific serum antibody responses in children with primary and recurrent respiratory syncytial virus infections. J Infect Dis. 1991; 164(1):15-21. DOI: 10.1093/infdis/164.1.15. View

Nagao Y, Koelle K . Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proc Natl Acad Sci U S A. 2008; 105(6):2238-43. PMC: 2538904. DOI: 10.1073/pnas.0709029105. View

Dunham E, Holmes E . Inferring the timescale of dengue virus evolution under realistic models of DNA substitution. J Mol Evol. 2007; 64(6):656-61. DOI: 10.1007/s00239-006-0278-5. View

Shrestha S, King A, Rohani P . Statistical inference for multi-pathogen systems. PLoS Comput Biol. 2011; 7(8):e1002135. PMC: 3158042. DOI: 10.1371/journal.pcbi.1002135. View

Ferguson N, Anderson R, Gupta S . The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens. Proc Natl Acad Sci U S A. 1999; 96(2):790-4. PMC: 15215. DOI: 10.1073/pnas.96.2.790. View

Grenfell B, Pybus O, Gog J, Wood J, Daly J, Mumford J . Unifying the epidemiological and evolutionary dynamics of pathogens. Science. 2004; 303(5656):327-32. DOI: 10.1126/science.1090727. View

COONEY M, Fox J, KENNY G . Antigenic groupings of 90 rhinovirus serotypes. Infect Immun. 1982; 37(2):642-7. PMC: 347580. DOI: 10.1128/iai.37.2.642-647.1982. View

10.

Martina B, Koraka P, Osterhaus A . Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev. 2009; 22(4):564-81. PMC: 2772360. DOI: 10.1128/CMR.00035-09. View

11.

Glass K, Xia Y, Grenfell B . Interpreting time-series analyses for continuous-time biological models--measles as a case study. J Theor Biol. 2003; 223(1):19-25. DOI: 10.1016/s0022-5193(03)00031-6. View

12.

Guzman M, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, Vazquez S . Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis. 2007; 13(2):282-6. PMC: 2725871. DOI: 10.3201/eid1302.060539. View

13.

Salje H, Lessler J, Endy T, Curriero F, Gibbons R, Nisalak A . Revealing the microscale spatial signature of dengue transmission and immunity in an urban population. Proc Natl Acad Sci U S A. 2012; 109(24):9535-8. PMC: 3386131. DOI: 10.1073/pnas.1120621109. View

14.

Nisalak A, Endy T, Nimmannitya S, Kalayanarooj S, Thisayakorn U, Scott R . Serotype-specific dengue virus circulation and dengue disease in Bangkok, Thailand from 1973 to 1999. Am J Trop Med Hyg. 2003; 68(2):191-202. View

15.

Kliks S, Nisalak A, BRANDT W, Wahl L, Burke D . Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989; 40(4):444-51. DOI: 10.4269/ajtmh.1989.40.444. View

16.

Sabin A . Research on dengue during World War II. Am J Trop Med Hyg. 1952; 1(1):30-50. DOI: 10.4269/ajtmh.1952.1.30. View

17.

Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R . Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Hum Vaccin. 2006; 2(2):60-7. DOI: 10.4161/hv.2.2.2555. View

18.

Ferguson N, Galvani A, Bush R . Ecological and immunological determinants of influenza evolution. Nature. 2003; 422(6930):428-33. DOI: 10.1038/nature01509. View

19.

Guzman M, Halstead S, Artsob H, Buchy P, Farrar J, Gubler D . Dengue: a continuing global threat. Nat Rev Microbiol. 2010; 8(12 Suppl):S7-16. PMC: 4333201. DOI: 10.1038/nrmicro2460. View

20.

Kochel T, Watts D, Gozalo A, Ewing D, Porter K, Russell K . Cross-serotype neutralization of dengue virus in Aotus nancymae monkeys. J Infect Dis. 2005; 191(6):1000-4. DOI: 10.1086/427511. View